Fig. 4: Impact of C@MSN-P-A8 on RAW264.7 osteoclast formation and bone resorption.
From: Bone-targeted celastrol nanocarrier suppresses osteoclastogenesis in postmenopausal osteoporosis
A TRAP staining to assess the effect of C@MSN-P-A8 on RAW264.7 osteoclast formation (Scale bar = 50 μm). B Immunofluorescence analysis of the influence of C@MSN-P-A8 on the F-actin ring in RAW264.7 cells (Scale bar = 50 μm); C Representative images stained using toluidine blue (Scale bar = 50 μm); (D) Bone resorption pit assay evaluating the effect of C@MSN-P-A8 on osteoclast bone resorption function (Scale bar = 25 μm). * indicates comparison between the two groups, ***P < 0.001. The cell experiments were performed in triplicate.
